SCHEMBL7679159

SCHEMBL7679159

O=C1/C(=C\c2ccccc2)c2ccccc2N1c1ccc2[nH]ccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
APP P05067 4/20 0.50
SNCA P37840 4/20 0.50
HCRTR1 O43613 1/20 0.50
ITGA4 P13612 3/20 0.42
ITGB7 P26010 3/20 0.42
PDE10A Q9Y233 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ERBB2 P04626 1/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
PKM P14618 1/20 0.38
HTT P42858 1/20 0.38
RORC P51449 1/20 0.38
CES2 O00748 1/20 0.37
BCHE P06276 1/20 0.37
CES1 P23141 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CYP2A6 P11509 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7679164 1.00 MAPT (0.50) MAPTAPPSNCAHCRTR1ITGA4
SCHEMBL7670343 0.77 APP (0.47) MAPTAPPSNCAHCRTR1ITGA4
SCHEMBL7670335 0.77 APP (0.47) MAPTAPPSNCAHCRTR1ITGA4
SCHEMBL803139 0.77 KMT2A (0.50) MAPTHCRTR1PDE10AKDM4EALDH1A1
SCHEMBL29158518 0.75 MAPT (0.66) MAPTAPPSNCAHCRTR1ITGA4
SCHEMBL7677880 0.74 APP (0.58) MAPTAPPSNCAHCRTR1ITGA4
SCHEMBL7677885 0.74 APP (0.58) MAPTAPPSNCAHCRTR1ITGA4
SCHEMBL7678890 0.72 APP (0.75) MAPTAPPSNCAHCRTR1ITGA4
SCHEMBL7678889 0.72 APP (0.75) MAPTAPPSNCAHCRTR1ITGA4
SCHEMBL7676181 0.71 APP (0.57) MAPTAPPSNCAHCRTR1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020028936-A1 1,3-disubstituted indolin-2-ones for neoplasia OSI PHARMACEUTICALS, INC. 2002-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028936-A1 1,3-disubstituted indolin-2-ones for neoplasia TP53, MYC, VHL MAPT 2381/4885APP 4305/4885SNCA 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.